Sage Therapeutics
The 12-month data showed that 50 mg of zuranolone was well-tolerated among adults with MDD.
Biogen’s Aduhelm (aducanumab) reported only $300,000 in third-quarter sales compared to original analyst average estimates of $10.79 million.
Sage Therapeutics and Biogen announced positive results from their ongoing clinical trials on the efficacy and safety of zuranolone in treating major depressive disorder and postpartum depression.
Life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
FDA has been actively greenlighting a number of efforts over the last few days to push therapies for rare or serious diseases that have largely unmet medical needs. Here’s a look.
It was a busy week for clinical trial announcements. Take a look.
Sage announced the termination of the REDWOOD and RAINFOREST studies of zuranolone, which is being assessed to treat both major depressive disorder and post-partum depression.
The study drug is a once-daily, two-week therapy developed by Sage Therapeutics and Biogen for major depressive disorder (MDD) and postpartum depression (PPD).
BioSpace looks at five of the top investor companies that support life sciences companies across the industry.
JOBS
IN THE PRESS